Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Clin Infect Dis. 2017 Oct 15;65(8):1308-1315. doi: 10.1093/cid/cix478.
Human immunodeficiency virus type 1 (HIV-1) persists in latently infected resting CD4+ T cells (rCD4 cells), posing a major barrier to curing HIV-1 infection. Previous studies have quantified this pool of latently infected cells in Americans; however, no study has quantified this reservoir in sub-Saharan Africans, who make up the largest population of HIV-1-infected individuals globally.
Peripheral blood was collected from 70 virally suppressed HIV-1-infected individuals from Rakai District, Uganda, who had initiated antiretroviral therapy (ART) during chronic infection. The quantitative viral outgrowth assay was used to determine frequency of latently infected rCD4 cells containing replication-competent virus. Multivariate regression was used to identify correlates of reservoir size and to compare reservoir size between this Ugandan cohort and a previously studied cohort of individuals from Baltimore, Maryland.
The median frequency of latently infected rCD4 cells in this Ugandan cohort was 0.36 infectious units per million cells (IUPM; 95% confidence interval, 0.26-0.55 IUPM), 3-fold lower than the frequency observed in the Baltimore cohort (1.08 IUPM; .72-1.49 IUPM; P < .001). Reservoir size in Ugandans was correlated positively with set-point viral load and negatively with duration of viral suppression.
Virally suppressed Ugandans had a 3-fold lower frequency of rCD4 cells latently infected with replication-competent HIV-1, compared with previous observations in a cohort of American patients, also treated with ART during chronic infection. The biological mechanism driving the observed smaller reservoir in Ugandans is of interest and may be of significance to HIV-1 eradication efforts.
人类免疫缺陷病毒 1 型(HIV-1)潜伏感染静止 CD4+T 细胞(rCD4 细胞),这对治愈 HIV-1 感染构成了主要障碍。以前的研究已经量化了美国人群中潜伏感染细胞的数量;然而,尚无研究量化撒哈拉以南非洲人群中这一病毒库的数量,而撒哈拉以南非洲人群是全球 HIV-1 感染人数最多的人群。
从乌干达拉凯区 70 名病毒抑制的 HIV-1 感染者中采集外周血,这些感染者在慢性感染期间开始接受抗逆转录病毒治疗(ART)。使用定量病毒扩增试验来确定含有复制能力病毒的潜伏感染 rCD4 细胞的频率。多变量回归用于确定储库大小的相关因素,并比较乌干达队列和马里兰州巴尔的摩队列之间的储库大小。
该乌干达队列中潜伏感染 rCD4 细胞的中位频率为每百万个细胞 0.36 个感染性单位(IUPM;95%置信区间,0.26-0.55 IUPM),比巴尔的摩队列中观察到的频率低 3 倍(1.08 IUPM;0.72-1.49 IUPM;P<.001)。乌干达人的储库大小与设定点病毒载量呈正相关,与病毒抑制持续时间呈负相关。
与慢性感染期间接受 ART 治疗的美国患者队列之前的观察结果相比,抑制病毒的乌干达人潜伏感染具有复制能力的 HIV-1 的 rCD4 细胞频率低 3 倍。乌干达人观察到的较小储库的生物学机制令人感兴趣,可能对 HIV-1 根除工作具有重要意义。